title: Growth hormone response to catecholamine depletion in unmedicated, remitted subjects with major depressive disorder and healthy controls.
abstract: We investigated whether the human growth hormone (HGH) response to catecholamine depletion differs between fully remitted patients with major depressive disorder and healthy control subjects. Fourteen unmedicated subjects with remitted major depressive disorder (RMDD) and 11 healthy control subjects underwent catecholamine depletion with oral α-methylparatyrosine (AMPT) in a randomized, placebo-controlled, double-blind crossover study. The main outcome measure was the serum level of HGH. The diagnosis × drug interaction for HGH serum concentration was significant (F₁,₂₃ = 7.66, P < 0.02). This interaction was attributable to the HGH level increasing after AMPT administration in the RMDD subjects but not in the healthy subjects. In the RMDD sample, the AMPT-induced increase in HGH concentration correlated inversely with AMPT-induced anxiety symptoms as assessed using the Beck Anxiety Inventory (r = -0.63, P < 0.02). There was a trend toward an inverse correlation of the AMPT-induced HGH concentration changes with AMPT-induced depressive symptoms as measured by the BDI (r = -0.53, P = 0.05). Following catecholamine depletion, the RMDD subjects were differentiated from control subjects by their HGH responses. This finding, together with the negative correlation between HGH response and AMPT-induced anxiety symptoms in RMDD subjects, suggests that AMPT administration results in a deeper nadir in central catecholaminergic transmission, as reflected by a greater disinhibition of HGH secretion, in RMDD subjects versus control subjects.
authors: University Hospital of Psychiatry, University of Bern, Bern, Switzerland.
authors: Philipp
authors: P
authors: Homan
authors: Wayne C
authors: WC
authors: Drevets
authors: Gregor
authors: G
authors: Hasler
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002395:Catecholamines / Q000096:biosynthesis / Q000172:deficiency*; D018592:Cross-Over Studies; D003865:Major Depressive Disorder / Q000097:blood* / Q000175:diagnosis / Q000201:enzymology / Q000523:psychology; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D019382:Human Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D019805:alpha-Methyltyrosine / Q000008:administration & dosage*
chemical_list: D002395:Catecholamines; D004791:Enzyme Inhibitors; D019382:Human Growth Hormone; D019805:alpha-Methyltyrosine; D011388:Prolactin; D014446:Tyrosine 3-Monooxygenase